Daniel Röshammar, Ph.D.

Principal Consultant & Team Leader

Bio

  • Joined Pharmetheus in 2018, actively working in client projects and as Project Portfolio Team Leader managing a team of MIDD Consultants.
  • Expertise includes trial design, pediatrics, and regulatory advice in therapeutic areas such as cardiovascular diseases, infectious diseases, and oncology.
  • Experience as Managing Director and Scientific Director at SGS Exprimo NV, Belgium, Senior Clinical Pharmacometrician and Section Director Clinical Pharmacometrics at AstraZeneca, Sweden, and Pharmacokineticist and Modeling and Simulation Specialist at Ferring Pharmaceuticals, Denmark.
  • M.Sc. in Pharmaceutical Sciences (2003) from Uppsala University, Sweden, and Ph.D. in Medical Sciences (2009) from Gothenburg University, Sweden.
LinkedInGoogle Scholar

Pharmetheus affiliated publications

Optimized infusion rates for N,N-dimethyltryptamine to achieve a target psychedelic intensity based on a modeling and simulation frameworkOptimizing infusion rates for N,N-dimethyltryptamine based on either a continuous variable model or a bounded integer modelPopulation Pharmacokinetic/Pharmacodynamic Modeling of the Psychedelic Experience Induced by N,N-dimethyltryptamine – Implications for Dose ConsiderationsN,N-dimethyltryptamine affects electroencephalography response in a concentration-dependent manner—A pharmacokinetic/pharmacodynamic analysisPharmacokinetic Modeling and Simulation Support for Age‐ and Weight‐Adjusted Dosing of Dabigatran Etexilate in Children with Venous ThromboembolismAnticoagulant Effects of Dabigatran on Coagulation Laboratory Parameters in Pediatric Patients: Combined Data from Five Pediatric Clinical TrialsPharmacokinetic Modelling and Simulation Support the Age and Body-Weight-Adjusted Dosing of Dabigatran Etexilate in Paediatric Patients with Venous Thromboembolism, PB1271Population Pharmacokinetic/Pharmacodynamic Modelling of the Psychedelic Experience Induced by N,N-dimethyltryptamineThe Population PKPD of Unacylated and Acylated Ghrelin Following Single Rising Doses of BI 1356225 in Healthy Subjects is Impacted by the Time Since Last MealAssessment of Expected Drug Exposure Relative Maximum Safety Limits in Early Phase Studies